⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Real-world Effectiveness of Intravenous Eptinezumab in Patients with Chronic Migraine and Previous Subcutaneous Preventive Migraine Treatment (P8-12.004)

Charles E. Argoff Steven Herzog Ryan A. Smith Seema Soni-Brahmbhatt Susanne F. Awad Divya Asher Fawad Khan

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate whether prior use of subcutaneous anti–calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs) impacts the real-world effectiveness of eptinezumab in patients with chronic migraine (CM).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Argoff et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677da4 https://doi.org/10.1212/wnl.0000000000204584

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1P.004 Real-world effectiveness of intravenous eptinezumab in patients with chronic migraine and previous subcutaneous preventive migraine treatment2024
2Real-world Effectiveness of Eptinezumab in Patients in Whom ≥1 Prior Anti-CGRP Preventive Treatment had Failed: 6-month Results for an Ongoing Prospective Study (P10-15.006)Cohort Study · 2026
3A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experienceCohort Study · 2025 · 11 citations
4Real-world Effectiveness of Eptinezumab in Chronic Migraine: A 4-year Retrospective Longitudinal Cohort Study (P10-15.003)Cohort Study · 2026
5Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registryCohort Study · 2026 · 1 citations